Mithra, a company dedicated to women’s health, has received €1.25 million milestone payment from Fuji Pharma under a license and supply agreement for its Estetrol (E4) native estrogen-based product Estelle in Japan and ASEAN territories. The payment was triggered by completion of interim reports from Phase 3 trials investigating Estelle for the treatment of dysmenorrhea or endometriosis. Fuji announced positive top-line results from the double-blind, placebo-controlled studies, showing the fi...